BACKGROUND AND RATIONALE: Cancer-related fatigue is a common severe symptom in breast cancer patients, especially during chemotherapy. Exercise appears to be promising in prevention or treatment of fatigue. Resistance training as an accompanying treatment to chemotherapy has been minimally investigated, yet might counteract muscle degradation and inflammation caused by many chemotherapeutics, and thus forestall or reduce fatigue. Previous exercise trials mostly compared the intervention with 'usual care'. Therefore, it is unclear to what extent the observed effects on fatigue are based on physical adaptations by exercise itself, or rather on psycho-social factors linked to the group support or attention by the trainer. METHODS AND DESIGN: The BEATE study is a randomized, controlled intervention trial comparing a 12-week supervised progressive resistance training program with a supervised group-based progressive muscle relaxation training in 100 patients with breast cancer under adjuvant chemotherapy. The primary endpoint is cancer-related fatigue; secondary endpoints include quality of life, depression, and cognitive capacity. In addition, isokinetic and isometric muscle strength, cardiorespiratory fitness, and body composition are measured, and biomarkers, such as inflammatory parameters, cortisol, and oxidative stress are analyzed in blood, saliva and urine. Safety of the resistance training during chemotherapy is monitored. DISCUSSION: Strengths of the BEATE study include the investigation of progressive resistance training parallel with chemotherapy, the choice of a control group that enables an evaluation of the physiological effects of exercise beyond potential psycho-social effects, and the comprehensive and high-quality assessment of physiological factors and biomarkers potentially related to fatigue.
RCT Entities:
BACKGROUND AND RATIONALE: Cancer-related fatigue is a common severe symptom in breast cancerpatients, especially during chemotherapy. Exercise appears to be promising in prevention or treatment of fatigue. Resistance training as an accompanying treatment to chemotherapy has been minimally investigated, yet might counteract muscle degradation and inflammation caused by many chemotherapeutics, and thus forestall or reduce fatigue. Previous exercise trials mostly compared the intervention with 'usual care'. Therefore, it is unclear to what extent the observed effects on fatigue are based on physical adaptations by exercise itself, or rather on psycho-social factors linked to the group support or attention by the trainer. METHODS AND DESIGN: The BEATE study is a randomized, controlled intervention trial comparing a 12-week supervised progressive resistance training program with a supervised group-based progressive muscle relaxation training in 100 patients with breast cancer under adjuvant chemotherapy. The primary endpoint is cancer-related fatigue; secondary endpoints include quality of life, depression, and cognitive capacity. In addition, isokinetic and isometric muscle strength, cardiorespiratory fitness, and body composition are measured, and biomarkers, such as inflammatory parameters, cortisol, and oxidative stress are analyzed in blood, saliva and urine. Safety of the resistance training during chemotherapy is monitored. DISCUSSION: Strengths of the BEATE study include the investigation of progressive resistance training parallel with chemotherapy, the choice of a control group that enables an evaluation of the physiological effects of exercise beyond potential psycho-social effects, and the comprehensive and high-quality assessment of physiological factors and biomarkers potentially related to fatigue.
Authors: Friederike Scharhag-Rosenberger; Rea Kuehl; Oliver Klassen; Kai Schommer; Martina E Schmidt; Cornelia M Ulrich; Joachim Wiskemann; Karen Steindorf Journal: J Cancer Surviv Date: 2015-02-26 Impact factor: 4.442
Authors: Martina E Schmidt; Joachim Wiskemann; Theron Johnson; Nina Habermann; Andreas Schneeweiss; Karen Steindorf Journal: Support Care Cancer Date: 2018-02-14 Impact factor: 3.603
Authors: Christina Titz; Simone Hummler; Martina E Schmidt; Michael Thomas; Martin Steins; Joachim Wiskemann Journal: Support Care Cancer Date: 2018-02-26 Impact factor: 3.603
Authors: Oliver Klassen; Martina E Schmidt; Cornelia M Ulrich; Andreas Schneeweiss; Karin Potthoff; Karen Steindorf; Joachim Wiskemann Journal: J Cachexia Sarcopenia Muscle Date: 2016-11-28 Impact factor: 12.910
Authors: Anasua Pal; Philipp Zimmer; Martina E Schmidt; Manuela Hummel; Cornelia M Ulrich; Joachim Wiskemann; Karen Steindorf Journal: Front Physiol Date: 2019-07-25 Impact factor: 4.566
Authors: Leidy Sofía Montaño-Rojas; Ena Monserrat Romero-Pérez; Carlos Medina-Pérez; María Mercedes Reguera-García; José Antonio de Paz Journal: Int J Environ Res Public Health Date: 2020-09-07 Impact factor: 3.390
Authors: Karin Potthoff; Martina E Schmidt; Joachim Wiskemann; Holger Hof; Oliver Klassen; Nina Habermann; Philipp Beckhove; Juergen Debus; Cornelia M Ulrich; Karen Steindorf Journal: BMC Cancer Date: 2013-03-28 Impact factor: 4.430